Urologix' Building Momentum, New COO Help Boost Stock 63% In November
This article was originally published in The Gray Sheet
Continued momentum in sales of Urologix' Targis microwave catheter-based system for treatment of benign prostatic hyperplasia and procedure kit revenues, as well as growing acceptance of a "per-procedure" marketing strategy and strong additions to top management, helped Urologix stock jump 62.7% in November. The issue gained 2 points to close at 5-3/16
You may also be interested in...
Acquisition of disposable medical glove maker Safeskin marks Kimberly-Clark's entrance into the $3 bil. worldwide latex and synthetic glove market and will boost sales of the firm's professional health care segment to approximately $950 mil. in 2000.
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.